Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 15, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference

HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
January 13, 2021 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
December 22, 2020 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021"

HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid...
December 11, 2020 11:32 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat

HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
December 10, 2020 09:28 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
November 17, 2020 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Participate in A.G.P.’s Virtual Healthcare Symposium

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
November 11, 2020 16:05 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results

HOUSTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for children and adults with...
November 04, 2020 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Report Third Quarter 2020 Financial Results

HOUSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing treatments for pediatric cancers, solid tumors and...
October 13, 2020 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at BIO Investor Forum Digital

HOUSTON, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief...
September 10, 2020 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at Upcoming Investor Conferences

HOUSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...